AI assistant
LIGAND PHARMACEUTICALS INC — Director's Dealing 2024
Mar 6, 2024
31289_dirs_2024-03-06_c4df5da0-5d39-49e4-9437-e04a9b19f657.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: LIGAND PHARMACEUTICALS INC (LGND)
CIK: 0000886163
Period of Report: 2024-03-05
Reporting Person: Aryeh Jason (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-03-05 | Common Stock | M | 2893 | $39.35 | Acquired | 74422 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-03-05 | Non-Qualified Stock Option (right to buy) | $39.35 | M | 2893 | Disposed | 2024-06-04 | Common Stock (2893) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 51594 | Indirect |
| Common Stock | 5025 | Indirect |
Footnotes
F1: All securities disclosed in this Form 4 are owned by certain funds managed by JALAA Equities, LP, JLV Investments, LP and affiliates (the "Funds"). Jason Aryeh is the General Partner of JALAA Equities, LP and a partner of JLV Investments, LP. By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, JALAA Equities, LP, JLV Investments, LP and affiliates and Mr. Aryeh may be deemed to be the beneficial owners of the securities beneficially owned by the Funds.
F2: This Option was previously reported as a Grant of 3,312 shares, which vested in full on April 24, 2015, at an exercise price of $67.53 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer.